공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

T Cell Specific Surface Glycoprotein CD28 : 파이프라인 리뷰

T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 366663
페이지 정보 영문 73 Pages
가격
US $ 3,500 ₩ 3,917,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,834,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,751,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


T Cell Specific Surface Glycoprotein CD28 : 파이프라인 리뷰 T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 73 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

T Cell Specific Surface Glycoprotein CD28을 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

T Cell Specific Surface Glycoprotein CD28 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단일요법/복합요법별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Atox Bio Ltd.
  • Bristol-Myers Squibb Company
  • OSE Immunotherapeutics
  • TheraMAB LLC

치료제 개요

휴지 상태인 프로젝트

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 16.09.09

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Alpine Immune Sciences Inc, H2 2019
  • Pipeline by Atox Bio Ltd, H2 2019
  • Pipeline by Avacta Life Sciences Ltd, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Five Prime Therapeutics Inc, H2 2019
  • Pipeline by Imugene Ltd, H2 2019
  • Pipeline by OSE Immunotherapeutics, H2 2019
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Pipeline by TheraMAB LLC, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 6 and 1 respectively. Similarly, the universities portfolio in Phase 0 stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Solid Tumor, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Multiple Sclerosis, Rheumatoid Arthritis, Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, Colon Cancer, Colorectal Cancer, Gastrointestinal Radiation Toxicity, Hemophagocytic Lymphohistiocytosis, Inflammatory Bowel Disease, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Skin And Soft Tissue Infections, Stem Cell Transplantation, Systemic Lupus Erythematosus and Uveitis.

Furthermore, this report also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
  • Alpine Immune Sciences Inc
  • Atox Bio Ltd
  • Avacta Life Sciences Ltd
  • Bristol-Myers Squibb Co
  • Five Prime Therapeutics Inc
  • Imugene Ltd
  • OSE Immunotherapeutics
  • Regeneron Pharmaceuticals Inc
  • TheraMAB LLC
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
  • ALPN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALPN-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bispecific Monoclonal Antibody to Target CD28 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FPT-155 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FR-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Target ICOS, CD28 and NCR3LG1 for Colon Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lulizumab pegol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target CD278, CD28 and HER2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Proteins to Agonize CD28 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REGN-5678 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • reltecimod sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAB-08 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vaccine to Target CD28 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
  • T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Alpine Immune Sciences presents ALPN-101 phase 1 healthy volunteer study data and details of upcoming phase I/II BALANCE GVHD study at the 61st American Society of Hematology annual meeting
  • Nov 12, 2019: Alpine Immune Sciences presents new ALPN-101 preclinical data at the 2019 American College of Rheumatology (ACR) Annual Meeting
  • Nov 09, 2019: Five Prime Therapeutics presents initial safety data from the phase 1 trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting
  • Nov 08, 2019: Alpine Immune Sciences presents new preclinical data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Nov 06, 2019: Alpine Immune Sciences announces oral presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition
  • Oct 30, 2019: Alpine Immune Sciences completes enrollment of phase I study of ALPN-101 and announces third quarter conference call
  • Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation of ALPN-101 at ACR/ARHP 2019 Annual Meeting
  • Oct 02, 2019: Alpine Immune Sciences announces upcoming scientific presentation on ALPN-202 at SITC 2019 Annual Meeting
  • Jun 18, 2019: Atox Bio announces exercise by BARDA of next option period to support continued development of reltecimod for NSTI
  • Apr 09, 2019: OSE Immunotherapeutics announces issuance of Canadian patent and notice of allowance of U.S. patent protecting CD28-Antagonist Immunotherapy FR104
  • Feb 19, 2019: Alpine Immune Sciences presents preclinical ALPN-101 GvHD data at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (TCT Meetings)
  • Feb 14, 2019: Atox Bio announces appointment of Robert Greif as chief commercial officer
  • Feb 12, 2019: Alpine Immune treats first patient in Phase I trial of ALPN-101
  • Dec 03, 2018: Alpine Immune sciences showcases key preclinical data at 60th American Society of Hematology Annual Meeting and Exposition
  • Nov 29, 2018: Alpine Immune Sciences announces ALPN-101 data to be included in oral presentation at 60th American Society of Hematology Annual Meeting and Exposition
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q